Learn how doggybone DNA (dbDNA™) vaccines offer a safe, scalable alternative to plasmid DNA for cancer immunotherapy, delivering strong immune responses without bacterial components. Download the full article to learn:…
Read More
This article explores the development of an optimized linear DNA vaccine for influenza using Touchlight’s dbDNA™ platform. By incorporating neuraminidase (NA) alongside haemagglutinin (HA) and leveraging DNA targeting sequences (DTS),…
Read More
This article explores how Touchlight’s enzymatically amplified linear dbDNA™ technology overcomes the limitations of traditional plasmid-based methods in lentiviral vector (LVV) manufacturing. By optimizing vector design and transfection conditions, the…
Read More
This article presents a comparative study between traditional plasmid DNA vaccines and novel enzymatically produced linear DNA constructs known as "Doggybones." These linear constructs, which exclude unnecessary bacterial elements, demonstrated…
Read More
CAR T cell therapy has shown remarkable success in treating blood cancers, but current production methods using viral vectors are extremely expensive, limiting patient access. In this groundbreaking study, researchers…
Read More
CAR T cell therapy has shown remarkable success in treating blood cancers, but current production methods using viral vectors are extremely expensive, limiting patient access. In this groundbreaking study, researchers…
Read More
The most effective way to end the COVID-19 pandemic is through the development of medical countermeasures to combat SARS-CoV-2 infection and disease. The rise of the variants has also illustrated…
Read More
Induced pluripotent stem cells (iPSCs) represent a transformative platform for regenerative medicine and cell therapy, but clinical success depends on safe and reliable reprogramming methods. This study reports the first…
Read More
LISA CAPRONI, PH.D. As the global demand for RNA-based therapeutics and vaccines accelerates, traditional plasmid DNA (pDNA) production methods often struggle to meet today’s biopharmaceutical landscape’s scalability and efficiency requirements.…
Read More
As advanced therapies continue to transform the healthcare landscape, the need for sustainable manufacturing solutions grows more critical. Traditional plasmid DNA (pDNA) production presents costly, resource-intensive challenges, threatening scalability and…
Read More
